DNA Sequencing of Liquid Biopsy Specimens Increases Accuracy of Prostate Cancer Diagnosis
By LabMedica International staff writers Posted on 12 Jan 2015 |
Next-generation sequencing analysis of DNA in the serum, a technique called liquid biopsy, can distinguish between prostate cancer patients, normal individuals, patients with benign hyperplasia, and those with noncancerous prostatitis.
Genomic instability resulting in copy number variation is characteristic of malignant transformation and may be identified through next-generation massive parallel sequencing. Tumor-specific cell free DNA (cfDNA) is released by dying cancer cells into the serum and plasma where it provides a real time, easily accessible target for this approach.
Investigators at Vanderbilt University (Nashville, TN USA) extracted DNA from serum of 204 patients with prostate cancer, 207 male controls, 10 patients with benign hyperplasia, and 10 with prostatitis. DNA was amplified by use of random primers, tagged with molecular identifiers, sequenced on a Life Technologies (Carlsbad, CA, USA) SOLID system, and aligned to the human genome.
Assessment of the results allowed the investigators to establish a model that discriminated prostate cancer from controls with an AUC (area under the curve) of 0.92 (0.87–0.95), reaching a diagnostic accuracy of 83%. Both benign prostatic hypertrophy and prostatitis could be distinguished from prostate cancer by use of cfDNA, with an accuracy of 90%.
"Based on the reported data and work in progress, I believe the "liquid biopsy" will revolutionize cancer diagnostics, not only before a patient begins therapy but also following patient responses to therapy," said contributing author Dr. William Mitchell, professor of pathology, microbiology, and immunology at Vanderbilt University. "Since cell-free DNA has a relatively short half-life in the circulation, sequencing of cell-free DNA soon after therapy may be used to detect minimal residual disease in solid tumors."
The study was published in the January 2015 issue of the journal Clinical Chemistry.
Related Links:
Vanderbilt University
Life Technologies
Genomic instability resulting in copy number variation is characteristic of malignant transformation and may be identified through next-generation massive parallel sequencing. Tumor-specific cell free DNA (cfDNA) is released by dying cancer cells into the serum and plasma where it provides a real time, easily accessible target for this approach.
Investigators at Vanderbilt University (Nashville, TN USA) extracted DNA from serum of 204 patients with prostate cancer, 207 male controls, 10 patients with benign hyperplasia, and 10 with prostatitis. DNA was amplified by use of random primers, tagged with molecular identifiers, sequenced on a Life Technologies (Carlsbad, CA, USA) SOLID system, and aligned to the human genome.
Assessment of the results allowed the investigators to establish a model that discriminated prostate cancer from controls with an AUC (area under the curve) of 0.92 (0.87–0.95), reaching a diagnostic accuracy of 83%. Both benign prostatic hypertrophy and prostatitis could be distinguished from prostate cancer by use of cfDNA, with an accuracy of 90%.
"Based on the reported data and work in progress, I believe the "liquid biopsy" will revolutionize cancer diagnostics, not only before a patient begins therapy but also following patient responses to therapy," said contributing author Dr. William Mitchell, professor of pathology, microbiology, and immunology at Vanderbilt University. "Since cell-free DNA has a relatively short half-life in the circulation, sequencing of cell-free DNA soon after therapy may be used to detect minimal residual disease in solid tumors."
The study was published in the January 2015 issue of the journal Clinical Chemistry.
Related Links:
Vanderbilt University
Life Technologies
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer